NeuroGenetics of Alzheimer’s Disease: Cross-Linking BDNF Brain-Derived Neurotrophic Factor in the Genetic Nexus of Type II Diabetes and Dementia
Article Sidebar
Main Article Content
Abstract
Background: Alzheimer’s disease and dementia are commonly associated with aging, particularly in the context of Type II Diabetes Mellitus (Type II DM), which is known to exacerbate micro and macrovascular complications that affect cognitive functions. The Brain-Derived Neurotrophic Factor (BDNF) gene has been implicated in the neurodegenerative processes that underscore these conditions.
Objective: This study aimed to investigate the expression of the BDNF gene in diabetic patients with dementia and analyze its correlation with cognitive impairment, to establish BDNF as a potential biomarker for early detection and therapeutic targeting.
Methods: A cohort of 102 patients with diabetic dementia and 32 healthy controls was enrolled. EDTA blood samples were collected and processed to measure BDNF serum levels using a Chemiluminescent Immunoassay (CLIA). Genomic DNA was isolated, and its integrity was confirmed via UV spectrophotometry and gel electrophoresis. The bisulfite DNA modification and Methylation-Specific PCR were conducted to analyze BDNF gene expression, followed by quantitative real-time PCR. Cognitive function was assessed using Mini-Mental State Examination (MMSE).
Results: The study revealed a significant decrease in BDNF serum levels in diabetic dementia patients (12.6 ng/mL) compared to healthy controls (34.8 ng/mL), with MMSE scores averaging at 13.2 and 24.6, respectively. BDNF gene expression showed a 4.1-fold decrease in the dementia group. Statistical analysis indicated that these differences were significant (p<0.05).
Conclusion: The reduced expression of BDNF in patients with diabetic dementia confirms its potential as a biomarker for cognitive impairment. Early detection and intervention strategies that modulate BDNF could ameliorate the impact of dementia in the context of diabetes.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Alzheimer's & Dementia: The Journal of the Alzheimer's Association. 2022 Alzheimer's disease facts and figures. Alzheimers Dement. 2022;18(4):700–789.
Saedi E, Gheini MR, Faiz F, Arami MA. Diabetes mellitus and cognitive impairments. World J Diabetes. 2016;7(17):412–422.
Silva MVF, Loures CMG, Alves LCV, de Souza LC, Borges KBG, Carvalho MDG. Alzheimer's disease: risk factors and potentially protective measures. J Biomed Sci. 2019;26(1):33.
Naegelin Y, Dingsdale H, Säuberli K, Schädelin S, Kappos L, Barde YA. Measuring and validating the levels of brain-derived neurotrophic factor in human serum. eNeuro. 2018;5(2):ENEURO.0419-17.2018.
Ng TKS, Ho CSH, Tam WWS, Kua EH, Ho RC. Decreased serum brain-derived neurotrophic factor (BDNF) levels in patients with Alzheimer's disease (AD): a systematic review and meta-analysis. Int J Mol Sci. 2019;20(2):257.
Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164–1178.
Tan BL, Norhaizan ME. Effect of high-fat diets on oxidative stress, cellular inflammatory response, and cognitive function. Nutrients. 2019;11(11):2579.
Shen L, Jia J. An overview of genome-wide association studies in Alzheimer's disease. Neurosci Bull. 2016;32(2):183–190.
Colucci-D'Amato L, Speranza L, Volpicelli F. Neurotrophic factor BDNF, physiological functions and therapeutic potential in depression, neurodegeneration and brain cancer. Int J Mol Sci. 2020;21(20):7777.
Ahmad R, Chowdhury K, Kumar S, Irfan M, Reddy GS, Akter F, Jahan D, Haque M. Diabetes Mellitus: A path to amnesia, personality, and behavior change. Biology. 2022;11(3):382.
Kim OY, Song J. The importance of BDNF and RAGE in diabetes-induced dementia. Pharmacol Res. 2020;160:105083.
Ab-Hamid N, Omar N, Ismail CAN, Long I. Diabetes and cognitive decline: challenges and future direction. World J Diabetes. 2023;14(6):795–807.
Mayeda ER, Whitmer RA, Yaffe K. Diabetes and cognition. Clin Geriatr Med. 2015;31(1):101-ix.
Cade WT. Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther. 2008;88(11):1322–1335.
Tyagi A, Pugazhenthi S. Targeting insulin resistance to treat cognitive dysfunction. Mol Neurobiol. 2021;58(6):2672–2691.
Sherwani SI, Khan HA, Ekhzaimy A, Masood A, Sakharkar MK. Significance of HbA1c test in diagnosis and prognosis of diabetic patients. Biomark Insights. 2016;11:95–104.
Rajmohan R, Reddy PH. Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer's disease neurons. J Alzheimers Dis. 2017;57(4):975–999.
Thériault P, ElAli A, Rivest S. High fat diet exacerbates Alzheimer's disease-related pathology in APPswe/PS1 mice. Oncotarget. 2016;7(42):67808–67827.
Gao L, Zhang Y, Sterling K, Song W. Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential. Transl Neurodegener. 2022;11(1):4.
Piancatelli D, Aureli A, Sebastiani P, Colanardi A, Del Beato T, Del Cane L, Sucapane P, Marini C, Di Loreto S. Gene- and gender-related decrease in serum BDNF levels in Alzheimer's disease. Int J Mol Sci. 2022;23(23):14599.
Bathina, S., & Das, U. N. (2015). Brain-derived neurotrophic factor and its clinical implications. Archives of medical science: AMS, 11(6), 1164–1178.
Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022). Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential. Translational neurodegeneration, 11(1), 4.
Piancatelli, D., Aureli, A., Sebastiani, P., Colanardi, A., Del Beato, T., Del Cane, L., Sucapane, P., Marini, C., & Di Loreto, S. (2022). Gene- and Gender-Related Decrease in Serum BDNF Levels in Alzheimer's Disease. International journal of molecular sciences, 23(23), 14599.